Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) traded up 5.5% on Monday . The company traded as high as $5.71 and last traded at $5.81. 107,046 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,335,229 shares. The stock had previously closed at $5.50.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on VIR. HC Wainwright reissued a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, February 28th. Leerink Partners lifted their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. The Goldman Sachs Group lowered their price objective on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Thursday, February 27th. Finally, Barclays upped their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $33.57.
Check Out Our Latest Stock Analysis on VIR
Vir Biotechnology Price Performance
The stock's 50-day simple moving average is $6.90 and its two-hundred day simple moving average is $8.05. The firm has a market capitalization of $844.95 million, a P/E ratio of -1.56 and a beta of 1.14.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.09. The firm had revenue of $12.37 million for the quarter, compared to analysts' expectations of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. On average, analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Insider Activity at Vir Biotechnology
In other news, Director George A. Scangos sold 10,964 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the transaction, the director now owns 708,295 shares of the company's stock, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the transaction, the executive vice president now owns 79,460 shares in the company, valued at $726,264.40. This trade represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 99,611 shares of company stock valued at $663,525. Insiders own 15.60% of the company's stock.
Institutional Trading of Vir Biotechnology
A number of large investors have recently made changes to their positions in VIR. Point72 Asia Singapore Pte. Ltd. bought a new stake in Vir Biotechnology during the 4th quarter valued at $42,000. GAMMA Investing LLC boosted its holdings in shares of Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock valued at $46,000 after buying an additional 5,972 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Vir Biotechnology in the fourth quarter valued at approximately $60,000. PNC Financial Services Group Inc. grew its stake in Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after buying an additional 1,999 shares during the last quarter. Finally, KBC Group NV boosted its holdings in Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after acquiring an additional 5,177 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Featured Articles
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
